Literature DB >> 28384863

Comparative Evaluation of Fosfomycin Activity with other Antimicrobial Agents against E.coli Isolates from Urinary Tract Infections.

Ahmed Sardar1, Sreekanth Reddy Basireddy2, Anwar Navaz3, Manisha Singh4, Vasanti Kabra5.   

Abstract

INTRODUCTION: Fosfomycin is a broad spectrum anti-microbial agent with activity against various bacterial agents. It is a bactericidal antibiotic which interferes with cell wall synthesis. Fosfomycin is rapidly absorbed orally and majority of the drug is excreted unchanged in urine with very high concentration levels achieved in urine after a single oral dose. Urine levels remain high for prolonged period which makes it a suitable drug in the treatment of Urinary Tract Infections (UTI). E.coli is the most common organism causing the UTI. With the inappropriate and inadvertent use of higher antibiotics, these bacterial isolates have acquired multidrug resistance for which treatment options are limited. AIM: To evaluate the in-vitro activity of fosfomycin against uropathogenic E.coli and to compare its activity with the other anti-microbial agents.
MATERIALS AND METHODS: This study was a prospective study done in the Department of Microbiology SVS Medical College, Mahbubnagar from Jan 2016 to Mar 2016. A total of 564 urine samples from suspected UTI cases were processed during the study period out of which 170 E.coli were isolated. Identification of the organisms were done by routine biochemical testing and antibiotic sensitivity testing was done by Kirby-Bauer disc diffusion testing according to the CLSI guidelines (M100-S23).
RESULTS: A total of 170 E.coli isolates were tested for antibiotic susceptibility. Out of 170 isolates 60 (35.30%) were isolated from males and 110 (64.70%) from females with male to female ratio of 1:1.83. Majority of the isolates were obtained from the age group of 21-30 years (25.8%). Antibiotics like fosfomycin, imipenem and methenamine mandelate showed the highest sensitivity with all the isolates (100%) being susceptible to these drugs. Whereas, least sensitivity was observed for amoxyclav (15.2%) followed by cefixime (16.4%) and norfloxacin (21%). Fosfomycin has shown very good in-vitro activity against all the tested isolates when compared with many other antibiotics.
CONCLUSION: In view of emergence of multidrug resistant pathogens, testing for old and forgotten antibiotics like fosfomycin is gaining importance. Because of its unique mechanism of action and low incidence of resistance it can be a potential therapeutic alternative in the treatment of UTI.

Entities:  

Keywords:  Antibiotics; Drug resistance; Methenamine; Oral formulation

Year:  2017        PMID: 28384863      PMCID: PMC5376875          DOI: 10.7860/JCDR/2017/23644.9440

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  19 in total

1.  Nitrofurantoin: preferred empiric therapy for community-acquired lower urinary tract infections.

Authors:  Burke A Cunha; Paul E Schoch; Jean R Hage
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

2.  Immunomodulatory effects of fosfomycin in an endotoxin model in human blood.

Authors:  Markus Zeitlinger; Claudia Marsik; Ilka Steiner; Robert Sauermann; Katja Seir; Bernd Jilma; Oswald Wagner; Christian Joukhadar
Journal:  J Antimicrob Chemother       Date:  2006-11-16       Impact factor: 5.790

3.  Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.

Authors:  Thomas M Hooton; Pacita L Roberts; Ann E Stapleton
Journal:  JAMA       Date:  2012-02-08       Impact factor: 56.272

Review 4.  The revival of fosfomycin.

Authors:  Argyris S Michalopoulos; Ioannis G Livaditis; Vassilios Gougoutas
Journal:  Int J Infect Dis       Date:  2011-09-25       Impact factor: 3.623

Review 5.  Fosfomycin: an old--new antibiotic.

Authors:  R Raz
Journal:  Clin Microbiol Infect       Date:  2011-09-13       Impact factor: 8.067

6.  Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.

Authors:  Husnu Pullukcu; Meltem Tasbakan; Oguz Resat Sipahi; Tansu Yamazhan; Sohret Aydemir; Sercan Ulusoy
Journal:  Int J Antimicrob Agents       Date:  2007-01       Impact factor: 5.283

7.  Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Simon Auer; Alexandra Wojna; Markus Hell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

8.  The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.

Authors:  Gian Carlo Schito; Kurt G Naber; Henry Botto; Juan Palou; Teresita Mazzei; Laura Gualco; Anna Marchese
Journal:  Int J Antimicrob Agents       Date:  2009-06-07       Impact factor: 5.283

9.  A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.

Authors:  Xiaojuan Xin; Li Jian; Xiaoying Xia; Bei Jia; Wenxiang Huang; Chongzhi Li; Changzheng Wang; Lixin Zhou; Xiuzhen Sun; Xinghuo Tang; Yijiang Huang; Yunkui Zhu; Weili Zhang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-12-09       Impact factor: 3.944

10.  Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients.

Authors:  V Niranjan; A Malini
Journal:  Indian J Med Res       Date:  2014-06       Impact factor: 2.375

View more
  2 in total

1.  Evaluation of in vitro susceptibility of fosfomycin among Enterobacteriaceae isolates from urine cultures: A study from Puducherry.

Authors:  Srirangaraj Sreenivasan; Arunava Kali; M V Pravin Charles; Seetha Kunigal
Journal:  J Lab Physicians       Date:  2019 Jul-Sep

2.  Susceptibility pattern of oral antimicrobials in uncomplicated UTI: Does fosfomycin still stand effective?

Authors:  Priyam Batra; Amit K Abrol; Stuti Gupta; Preeti Pushpan; Rajendra Kumar
Journal:  J Family Med Prim Care       Date:  2020-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.